These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 16246511)

  • 1. Strategies for improving the functionality of an affinity bioreactor.
    Wang T; Yang Z; Emregul E; David A; Balthasar JP; Liang J; Yang VC
    Int J Pharm; 2005 Dec; 306(1-2):132-41. PubMed ID: 16246511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A GPIIb/IIIa bioreactor for specific treatment of immune thrombocytopenic purpura, an autoimmune disease. Preparation, in vitro characterization, and preliminary proof-of-concept animal studies.
    Emregul E; David A; Balthasar JP; Yang VC
    J Biomed Mater Res A; 2005 Dec; 75(3):648-55. PubMed ID: 16108027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A filter device for the prevention of both heparin- and protamine-induced complications associated with extracorporeal therapy.
    Yang VC; Teng CL; Kim JS
    Biomed Instrum Technol; 1990; 24(6):433-9. PubMed ID: 2261582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PEG-modified protamine with improved pharmacological/pharmaceutical properties as a potential protamine substitute: synthesis and in vitro evaluation.
    Chang LC; Lee HF; Chung MJ; Yang VC
    Bioconjug Chem; 2005; 16(1):147-55. PubMed ID: 15656586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of protamine hollow-fiber device for extracorporeal heparin removal.
    Liang JF; Emregul E; Yang VC
    Blood Purif; 2004; 22(2):198-202. PubMed ID: 15044818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protamine immobilization and heparin adsorption on the protamine-bound cellulose fiber membrane.
    Kim JS; Yang AJ; Yang VC
    Biotechnol Bioeng; 1992 Feb; 39(4):450-6. PubMed ID: 18600967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Poly-L-lysine amplification of protamine immobilization and heparin adsorption.
    Zhang Y; Singh VK; Yang VC
    J Biomed Mater Res; 1998 Nov; 42(2):182-7. PubMed ID: 9773814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A protamine filter for extracorporeal blood heparin removal.
    Teng CL; Kim JS; Port FK; Wakefield TW; Till GO; Yang VC
    ASAIO Trans; 1988; 34(3):743-6. PubMed ID: 3196594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel approach for optimizing the capacity and efficacy of a protamine filter for clinical extracorporeal heparin removal.
    Zhang Y; Singh VK; Yang VC
    ASAIO J; 1998; 44(5):M368-73. PubMed ID: 9804453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High salt stability and protein resistance of poly(L-lysine)-g-poly(ethylene glycol) copolymers covalently immobilized via aldehyde plasma polymer interlayers on inorganic and polymeric substrates.
    Blättler TM; Pasche S; Textor M; Griesser HJ
    Langmuir; 2006 Jun; 22(13):5760-9. PubMed ID: 16768506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heparin removal from blood using poly(L-lysine) immobilized hollow fiber.
    Ma X; Mohammad SF; Kim SW
    Biotechnol Bioeng; 1992 Aug; 40(4):530-6. PubMed ID: 18601148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparison of two schemes of administering the Russian protamine sulfate after extracorporeal circulation in cardiosurgical patients].
    Charnaia MA; Morozov IuA; Gladysheva VG; Isaeva AM
    Anesteziol Reanimatol; 2006; (5):31-3. PubMed ID: 17184058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A protamine filter for extracorporeal heparin removal. Development, testing, blood compatibility evaluation, and future direction.
    Byun Y; Yun JH; Han IS; Fu Y; Shanberge JN; Yang VC
    ASAIO J; 1995; 41(3):M301-5. PubMed ID: 8573812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can extra protamine eliminate heparin rebound following cardiopulmonary bypass surgery?
    Teoh KH; Young E; Blackall MH; Roberts RS; Hirsh J
    J Thorac Cardiovasc Surg; 2004 Aug; 128(2):211-9. PubMed ID: 15282457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficiency of polymer beads in the removal of heparin: toward the development of a novel reactor.
    Varghese MS; Hildebrandt D; Glasser D; Crowther NJ; Rubin DM
    Artif Cells Blood Substit Immobil Biotechnol; 2006; 34(4):419-32. PubMed ID: 16818415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heparin removal after cardiopulmonary bypass in a patient with adverse reaction to protamine.
    Tevaearai HT; Jegger D; Mueller XM; Horisberger J; von Segesser LK
    Thorac Cardiovasc Surg; 1998 Oct; 46(5):303-4. PubMed ID: 9885123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemical and pharmacological aspects of neutralization of heparins from different animal sources by protamine.
    Glauser BF; Santos GRC; Silva JD; Tovar AMF; Pereira MS; Vilanova E; Mourão PAS
    J Thromb Haemost; 2018 Sep; 16(9):1789-1799. PubMed ID: 29968421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A less toxic heparin antagonist--low molecular weight protamine.
    Liang JF; Zhen L; Chang LC; Yang VC
    Biochemistry (Mosc); 2003 Jan; 68(1):116-20. PubMed ID: 12693985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low molecular weight protamine as nontoxic heparin/low molecular weight heparin antidote (III): preliminary in vivo evaluation of efficacy and toxicity using a canine model.
    Lee LM; Chang LC; Wrobleski S; Wakefield TW; Yang VC
    AAPS PharmSci; 2001; 3(3):E19. PubMed ID: 11741270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heparin-protamine does not aggravate local LPS-provoked leukocytic inflammation in vivo.
    Schramm R; Nickels RM; Harder Y; Langer F; Menger MD; Schäfers HJ
    Thorac Cardiovasc Surg; 2006 Dec; 54(8):506-11. PubMed ID: 17151963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.